Cargando…
An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction
BACKGROUND: Inclusion of ethnic/racial minorities in clinical trials is essential to fully assess therapeutic efficacy. It is well-known that populations respond dissimilarly to interventions. Our objective is to analyze the inclusion of minority men in clinical trials for erectile dysfunction (ED)....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450121/ https://www.ncbi.nlm.nih.gov/pubmed/36092973 http://dx.doi.org/10.1016/j.conctc.2022.100986 |
_version_ | 1784784455345373184 |
---|---|
author | Saltzman, Russell G. Zucker, Isaac Campbell, Katherine Gandhi, Deep A. Otiono, Kikachukwu Weber, Alexander Masterson, Thomas A. Ramasamy, Ranjith |
author_facet | Saltzman, Russell G. Zucker, Isaac Campbell, Katherine Gandhi, Deep A. Otiono, Kikachukwu Weber, Alexander Masterson, Thomas A. Ramasamy, Ranjith |
author_sort | Saltzman, Russell G. |
collection | PubMed |
description | BACKGROUND: Inclusion of ethnic/racial minorities in clinical trials is essential to fully assess therapeutic efficacy. It is well-known that populations respond dissimilarly to interventions. Our objective is to analyze the inclusion of minority men in clinical trials for erectile dysfunction (ED). METHODS: We searched ClinicalTrials.gov for the disease keyword: “Erectile Dysfunction” and used “Prostate Cancer” for comparison. Completed trials which reported demographic data were included for analysis. Literature was reviewed to determine the prevalence of ED and prostate cancer (PC) among Hispanic, Black, White, and Asian men. The proportion of individuals of each group that participated in trials is divided by the proportion of each group in the disease population to calculate the “Participation to Prevalence Ratio” (PPR). PPRs between 0.8 and 1.2 indicates adequate representation, <0.8 is under-representation and >1.2 is over-representation. RESULTS: A total of 312 trials were assessed: 289 for prostate cancer and 23 for ED. Hispanic men comprised 11.8% of ED trial participants and 4.6% of prostate cancer trial participants, yet represented 18% of ED patients and 7.3% of PC patients. Black/African-American (AA) men accounted for 10.2% of ED trial participants and 9.4% of PC trial participants, but comprise 16% of ED patients, and 16.3% of PC patients. Hispanic and AA men are under-represented in trials for ED and Prostate Cancer (Hispanic ED PPR = 0.66; Hispanic PC PPR = 0.63; AA ED PPR = 0.64; AA PC PPR = 0.58). CONCLUSION: Our analysis shows that both Hispanic and AA men are underrepresented in both ED and PC clinical trials. |
format | Online Article Text |
id | pubmed-9450121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94501212022-09-08 An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction Saltzman, Russell G. Zucker, Isaac Campbell, Katherine Gandhi, Deep A. Otiono, Kikachukwu Weber, Alexander Masterson, Thomas A. Ramasamy, Ranjith Contemp Clin Trials Commun Article BACKGROUND: Inclusion of ethnic/racial minorities in clinical trials is essential to fully assess therapeutic efficacy. It is well-known that populations respond dissimilarly to interventions. Our objective is to analyze the inclusion of minority men in clinical trials for erectile dysfunction (ED). METHODS: We searched ClinicalTrials.gov for the disease keyword: “Erectile Dysfunction” and used “Prostate Cancer” for comparison. Completed trials which reported demographic data were included for analysis. Literature was reviewed to determine the prevalence of ED and prostate cancer (PC) among Hispanic, Black, White, and Asian men. The proportion of individuals of each group that participated in trials is divided by the proportion of each group in the disease population to calculate the “Participation to Prevalence Ratio” (PPR). PPRs between 0.8 and 1.2 indicates adequate representation, <0.8 is under-representation and >1.2 is over-representation. RESULTS: A total of 312 trials were assessed: 289 for prostate cancer and 23 for ED. Hispanic men comprised 11.8% of ED trial participants and 4.6% of prostate cancer trial participants, yet represented 18% of ED patients and 7.3% of PC patients. Black/African-American (AA) men accounted for 10.2% of ED trial participants and 9.4% of PC trial participants, but comprise 16% of ED patients, and 16.3% of PC patients. Hispanic and AA men are under-represented in trials for ED and Prostate Cancer (Hispanic ED PPR = 0.66; Hispanic PC PPR = 0.63; AA ED PPR = 0.64; AA PC PPR = 0.58). CONCLUSION: Our analysis shows that both Hispanic and AA men are underrepresented in both ED and PC clinical trials. Elsevier 2022-08-28 /pmc/articles/PMC9450121/ /pubmed/36092973 http://dx.doi.org/10.1016/j.conctc.2022.100986 Text en © 2022 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Saltzman, Russell G. Zucker, Isaac Campbell, Katherine Gandhi, Deep A. Otiono, Kikachukwu Weber, Alexander Masterson, Thomas A. Ramasamy, Ranjith An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction |
title | An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction |
title_full | An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction |
title_fullStr | An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction |
title_full_unstemmed | An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction |
title_short | An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction |
title_sort | evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450121/ https://www.ncbi.nlm.nih.gov/pubmed/36092973 http://dx.doi.org/10.1016/j.conctc.2022.100986 |
work_keys_str_mv | AT saltzmanrussellg anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT zuckerisaac anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT campbellkatherine anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT gandhideepa anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT otionokikachukwu anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT weberalexander anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT mastersonthomasa anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT ramasamyranjith anevaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT saltzmanrussellg evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT zuckerisaac evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT campbellkatherine evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT gandhideepa evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT otionokikachukwu evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT weberalexander evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT mastersonthomasa evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction AT ramasamyranjith evaluationofracebasedrepresentationamongmenparticipatinginclinicaltrialsforprostatecanceranderectiledysfunction |